Abstract
In a computational study using the force field method MM+, the known anticancer drug Titanocene Y was reacted with its biological target, which is believed to be double-stranded DNA. It was found that after the loss of two chloride ligands, the substituted titanocene dication conveniently coordinates strongly to a phosphate group by replacing a counter ion. In addition, the two p-methoxybenzyl groups have exactly the right length and flexibility to coordinate to two sodium counter ions bonded to two neighbouring phosphate groups, which allows Titanocene Y to become a chelating ligand strongly bonded to the surface of double-stranded DNA.
Keywords: Anticancer drug, Titanocene, DNA, Phosphate backbone, Chelating ligand
Letters in Drug Design & Discovery
Title: The Interaction of Titanocene Y with Double-Stranded DNA: A Computational Study
Volume: 5 Issue: 5
Author(s): Matthias Tacke
Affiliation:
Keywords: Anticancer drug, Titanocene, DNA, Phosphate backbone, Chelating ligand
Abstract: In a computational study using the force field method MM+, the known anticancer drug Titanocene Y was reacted with its biological target, which is believed to be double-stranded DNA. It was found that after the loss of two chloride ligands, the substituted titanocene dication conveniently coordinates strongly to a phosphate group by replacing a counter ion. In addition, the two p-methoxybenzyl groups have exactly the right length and flexibility to coordinate to two sodium counter ions bonded to two neighbouring phosphate groups, which allows Titanocene Y to become a chelating ligand strongly bonded to the surface of double-stranded DNA.
Export Options
About this article
Cite this article as:
Tacke Matthias, The Interaction of Titanocene Y with Double-Stranded DNA: A Computational Study, Letters in Drug Design & Discovery 2008; 5 (5) . https://dx.doi.org/10.2174/157018008784912036
DOI https://dx.doi.org/10.2174/157018008784912036 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Diabetes and Pancreas: Why So Difficult? Potential Mechanisms of Elevated Serum Pancreatic Enzymes
Current Medicinal Chemistry The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry 3D-QSAR and Docking Studies of 4-morpholinopyrrolopyrimidine Derivatives as Potent mTOR Inhibitors
Letters in Drug Design & Discovery Glutathione Transferases as Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Synthesis and Evaluation of Anticancer Activity of 5-Ylidene-4- Aminothiazol-2(5H)-one Derivatives
Medicinal Chemistry Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC)
Current Cancer Drug Targets Blockade of Jagged/Notch Pathway Abrogates Transforming Growth Factor β2-Induced Epithelial-Mesenchymal Transition in Human Retinal Pigment Epithelium Cells
Current Molecular Medicine